{"id":416696,"date":"2021-01-19T08:18:51","date_gmt":"2021-01-19T13:18:51","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=416696"},"modified":"2021-01-19T08:18:51","modified_gmt":"2021-01-19T13:18:51","slug":"cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/","title":{"rendered":"CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\/12pm PST"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\/12pm PST<\/b><\/p>\n<p>OXNARD, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.curepharmaceutical.com%2F&amp;esheet=52363554&amp;newsitemid=20210119005340&amp;lan=en-US&amp;anchor=CURE+Pharmaceutical+Holding+Corp.&amp;index=1&amp;md5=49beff5717ac930274ae3d5f1fa2c6f5\">CURE Pharmaceutical Holding Corp.<\/a> (OTC: CURR), a technology-focused, vertically integrated drug delivery and product development company in the pharmaceutical and health &amp; wellness space, announced today that the Company\u2019s Chief Executive Officer Rob Davidson will be presenting virtually at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nobleconference.com%2Fseventeen%23home&amp;esheet=52363554&amp;newsitemid=20210119005340&amp;lan=en-US&amp;anchor=NobleCon17&amp;index=2&amp;md5=83c69b9eeaf2957a69d5aaf7d2f76f79\">NobleCon17<\/a>, Noble Capital Markets\u2019 Seventeenth Annual Institutional Investor Conference, on Tuesday, January 19, at 3:00 p.m. EST.\n<\/p>\n<p>\nDavidson will discuss how CURE continues to develop its position as a global health and wellness leader through its recent acquisition of <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fseralabshealth.com%2F&amp;esheet=52363554&amp;newsitemid=20210119005340&amp;lan=en-US&amp;anchor=Sera+Labs&amp;index=3&amp;md5=e2421852cd8c382b55f845fac8ddb75b\">Sera Labs<\/a>. He will also provide an update on CURE\u2019s recently approved Investigational New Drug (IND) application for CUREfilm Blue\u2122 intended to treat erectile dysfunction (ED) using the Company\u2019s proprietary oral thin-film technology. Lastly, he will highlight the Company\u2019s 2021 fiscal strategy and the types of Company announcements supporters and investors can expect in the near future.\n<\/p>\n<p>\n\u201cCURE is heading into this fiscal year incredibly well positioned with extensive distribution, direct-to-consumer and marketing channels,\u201d said Davidson. \u201cWe have spent years developing our proprietary delivery mechanisms and pharmaceutical products. Meanwhile, Sera Labs has launched a number of exciting new consumer products since we joined forces and we look forward to growing this product portfolio with additional products that combine CURE\u2019s compelling delivery technology and Sera Labs\u2019 consumer products innovation. I look forward to discussing this progress and sharing additional insight into these milestones with conference attendees.\u201d\n<\/p>\n<p>\nThose who wish to attend the conference can register at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.noblecon17.com&amp;esheet=52363554&amp;newsitemid=20210119005340&amp;lan=en-US&amp;anchor=www.noblecon17.com&amp;index=4&amp;md5=bc68cd15e517ef727e0f6d3cd7f52d5e\">www.noblecon17.com<\/a> with no cost to attend.\n<\/p>\n<p>\nFor those who cannot attend the live presentation, a video webcast of the presentation will be available the following day on CURE\u2019s website <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.curepharmaceutical.com%2Finvestors%2F&amp;esheet=52363554&amp;newsitemid=20210119005340&amp;lan=en-US&amp;anchor=here&amp;index=5&amp;md5=ecf73cf3e0f5c0cf31c5c09e5ec7bc52\">here<\/a> and through the Noble Capital Markets\u2019 Conference website <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnoble.mediasite.com%2FMediasite%2FPlay%2F5af58fca3c1947e5bb9aa612b5c2b21a1d&amp;esheet=52363554&amp;newsitemid=20210119005340&amp;lan=en-US&amp;anchor=here&amp;index=6&amp;md5=dd1b00b2a4643d7bbc31e46e46a08591\">here<\/a>. Additionally, the webcast and presentation will be archived on the NobleCon website and on Channelchek.com for 90 days following the event.\n<\/p>\n<p><b>About Noble Capital Markets, Inc.<\/b><\/p>\n<p>\nNoble Capital Markets is a research driven boutique investment bank that has supported small &amp; microcap companies since 1984. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the last decade+. In 2018, Noble launched <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.channelchek.com%2F&amp;esheet=52363554&amp;newsitemid=20210119005340&amp;lan=en-US&amp;anchor=www.channelchek.com&amp;index=7&amp;md5=83689b222af8b16348f941e6fcd3bddb\">www.channelchek.com<\/a> \u2013 an investment community dedicated exclusively to small and micro-cap companies and their industries.\n<\/p>\n<p><b>About CURE Pharmaceutical Holding Corp.<\/b><\/p>\n<p>\nCURE Pharmaceutical<sup>\u00ae<\/sup> is the pioneering developer of CUREform\u2122, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.\n<\/p>\n<p>\nAs a vertically integrated company, CURE\u2019s 25,000 square foot, FDA-registered, NSF<sup>\u00ae<\/sup> and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.\n<\/p>\n<p><b><i>Forward Looking Statement<\/i><\/b><\/p>\n<p><i>Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (\u201cSecurities Act\u201d), and Section 21E of the Securities Exchange Act of 1934, as amended (\u201cExchange Act\u201d), which are usually identified by the use of words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cseeks,\u201d \u201cshould,\u201d \u201cwill,\u201d and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE\u2019s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210119005340r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210119005340\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210119005340\/en\/<\/a><\/span><\/p>\n<p><span class=\"bwuline\">Licensing Contact:<br \/>\n<\/span><br \/>Jonathan Berlent<br \/>\n<br \/>Chief Business Officer<br \/>\n<br \/>Cure Pharmaceutical<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Jberlent@curepharma.com\">Jberlent@curepharma.com<br \/>\n<\/a><br \/>516.660.9148<\/p>\n<p><span class=\"bwuline\">Investment Contact:<br \/>\n<\/span><br \/>Gary Zwetchkenbaum<br \/>\n<br \/>Plum Tree Consulting LLC<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:gzplumtree@gmail.com\">gzplumtree@gmail.com<br \/>\n<\/a><br \/>516.455.7662<\/p>\n<p><span class=\"bwuline\">Media Contact:<br \/>\n<\/span><br \/>Kathryn Brown<br \/>\n<br \/>CMW Media<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:cure@cmwmedia.com\">cure@cmwmedia.com<br \/>\n<\/a><br \/>858.264.6600\n<\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Pharmaceutical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\/12pm PST OXNARD, Calif.&#8211;(BUSINESS WIRE)&#8211;CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology-focused, vertically integrated drug delivery and product development company in the pharmaceutical and health &amp; wellness space, announced today that the Company\u2019s Chief Executive Officer Rob Davidson will be presenting virtually at NobleCon17, Noble Capital Markets\u2019 Seventeenth Annual Institutional Investor Conference, on Tuesday, January 19, at 3:00 p.m. EST. Davidson will discuss how CURE continues to develop its position as a global health and wellness leader through its recent acquisition of Sera Labs. He will also provide an update on CURE\u2019s recently approved Investigational New Drug (IND) application for CUREfilm Blue\u2122 intended to treat erectile dysfunction &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\/12pm PST&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-416696","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\/12pm PST - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\/12pm PST - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\/12pm PST OXNARD, Calif.&#8211;(BUSINESS WIRE)&#8211;CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology-focused, vertically integrated drug delivery and product development company in the pharmaceutical and health &amp; wellness space, announced today that the Company\u2019s Chief Executive Officer Rob Davidson will be presenting virtually at NobleCon17, Noble Capital Markets\u2019 Seventeenth Annual Institutional Investor Conference, on Tuesday, January 19, at 3:00 p.m. EST. Davidson will discuss how CURE continues to develop its position as a global health and wellness leader through its recent acquisition of Sera Labs. He will also provide an update on CURE\u2019s recently approved Investigational New Drug (IND) application for CUREfilm Blue\u2122 intended to treat erectile dysfunction &hellip; Continue reading &quot;CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\/12pm PST&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-19T13:18:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210119005340r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\\\/12pm PST\",\"datePublished\":\"2021-01-19T13:18:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\\\/\"},\"wordCount\":834,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210119005340r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\\\/\",\"name\":\"CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\\\/12pm PST - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210119005340r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-01-19T13:18:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210119005340r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210119005340r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\\\/12pm PST\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\/12pm PST - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/","og_locale":"en_US","og_type":"article","og_title":"CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\/12pm PST - Market Newsdesk","og_description":"CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\/12pm PST OXNARD, Calif.&#8211;(BUSINESS WIRE)&#8211;CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology-focused, vertically integrated drug delivery and product development company in the pharmaceutical and health &amp; wellness space, announced today that the Company\u2019s Chief Executive Officer Rob Davidson will be presenting virtually at NobleCon17, Noble Capital Markets\u2019 Seventeenth Annual Institutional Investor Conference, on Tuesday, January 19, at 3:00 p.m. EST. Davidson will discuss how CURE continues to develop its position as a global health and wellness leader through its recent acquisition of Sera Labs. He will also provide an update on CURE\u2019s recently approved Investigational New Drug (IND) application for CUREfilm Blue\u2122 intended to treat erectile dysfunction &hellip; Continue reading \"CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\/12pm PST\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-19T13:18:51+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210119005340r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\/12pm PST","datePublished":"2021-01-19T13:18:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/"},"wordCount":834,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210119005340r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/","name":"CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\/12pm PST - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210119005340r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-01-19T13:18:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210119005340r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210119005340r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-to-present-at-2021-noblecon17-on-tuesday-january-19-at-3pm-est-12pm-pst\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST\/12pm PST"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=416696"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416696\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=416696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=416696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=416696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}